Conoa-B (02162.HK): CM310 SAR phase III clinically successful product is expected to be approved within the year

中金公司Apr 29 16:41

Conoa-B (02162.HK): CM310 will soon be commercialized with differentiated pipeline layout in the early stages

廣發證券Apr 29 00:00

Conoa-B (2162.HK): Exclusive opportunity to reach the end of phase III allergic rhinitis

華泰證券Apr 28 00:00

Keji Pharmaceutical-B (02171.HK): CT053 commercialization implementation looks forward to overseas breakthroughs

浙商證券Apr 25 13:26

Conoa-B (2162.HK): The pipeline is progressing smoothly and is about to enter a new commercialization cycle

長江證券Apr 15 14:26

Lepu Bio-B (02157.HK) In-depth Research Report: ADC pipelines are rich in IO+ADC leading layout

華創證券Apr 13 00:00

Goli Pharmaceutical-B (1672.HK) 2023 Annual Results Announcement Comment: Losses narrowed sharply year over year, focus on multi-milestone events catalyzed

東北證券Apr 8 00:00

Keji Pharmaceutical (2171.HK): Seckaize has been approved for marketing and commercial release can be expected

國泰君安Apr 7 00:00

Conoa-B (2162.HK): CM310 is expected to be approved by the end of the year and multiple pipelines will continue to advance

國泰君安Apr 3 14:16

Baiaosetu (2315.HK) 2023 review: Overseas revenue is growing rapidly, Qianmu Wanbang has completed phased R&D, and the self-research pipeline is successfully authorized and transferred to the outside world

海通國際Apr 3 00:00

Eagle Eye Technology-B (2251.HK) Immediate Review: Rapid Revenue Growth, Broad Prospects for Medical AI

國元國際Apr 2 00:00

Conoa-B (02162.HK): Commercialization of Sproximab is imminent, optimistic about domestic sales potential

國信證券Apr 1 18:51

Xinwei Medical-B (06609.HK): Expected volume of therapeutic products in 2023 is slightly lower than expected

中金公司Apr 1 18:06

Genting Xinyao (01952.HK): Nifukang will soon start selling during the year, focus on the future volume of products

中金公司Mar 31 00:00

Kunbo Medical-B (2216.HK): Rapid growth in endogenous income, looking forward to continued improvement

華泰證券Mar 31 00:00

Conoa-B (2162.HK): Immediate launch of self-exempt products, R&D and innovation are progressing steadily

中信建投證券Mar 30 00:00

Eagle Eye Technology-B (02251.HK): 2023 results are in line with market expectations, further commercialization implemented

中金公司Mar 29 07:51

Conoa-B (2162.HK): Forge ahead and take the lead

華泰證券Mar 28 16:16

Conoa-B (02162.HK): CM310 is expected to be approved for listing within the year, focusing on commercialization

中金公司Mar 28 08:06

Yasheng Pharmaceutical (6855.HK): Multiple Indications Continue to Accelerate Overseas Progress

西南證券Mar 28 00:00